Skip to main content
Figure 3 | BMC Nephrology

Figure 3

From: Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

Figure 3

Changes in phosphate and calcium levels throughout the study. (A) Serum phosphate, (B) 24-h urinary phosphate excretion, (C) serum total calcium, (D) serum calcium × phosphate product, (E) 24-h urinary calcium excretion and (F) estimated daily dietary phosphate intake. Graphs show mean values ± standard deviation. LC, lanthanum carbonate; PBO, placebo.

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us

\